82732-02-3

Basic information

• Product Name: 3-bromobenzyl methanesulfonate
• Synonyms: 3-bromobenzyl methanesulfonate
• CAS NO: 82732-02-3
• Molecular Weight: 265.128
• Mol File: 82732-02-3.mol

Chemical Properties

• CAS DataBase Reference: 3-bromobenzyl methanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromobenzyl methanesulfonate(82732-02-3)
• EPA Substance Registry System: 3-bromobenzyl methanesulfonate(82732-02-3)

Safety Data

• Hazardous Substances Data: 82732-02-3(Hazardous Substances Data)

Upstream product

• 15852-73-0 (3-Bromophenyl)methanol 
• 124-63-0 methanesulfonyl chloride 
• 3132-99-8 m-bromobenzoic aldehyde 

Downstream Products

• 456-43-9 1-bromo-3-(fluoromethyl)benzene 
• 82732-03-4 1,1'-(1,2-ethanediyl)bis-3-bromobenzene 
• 82732-05-6 2-<3-fluoromethyl)phenyl>-2-propyl chloride 
• 82732-04-5 2-<3-(fluoromethyl)phenyl>-2-propanol 
• 774192-14-2 2-[(3-bromobenzyl)amino]ethanol 
• 126799-86-8 1-(azidomethyl)-3-bromobenzene 

Relevant articles and documents

Compound targeting to I-type PRMT and preparation method and application of compound

The invention relates to the technical field of chemical drugs, in particular to a compound targeting to I-type PRMT, and a preparation method and application thereof. The compound A and a pharmaceutically acceptable salt thereof belong to covalent inhibi

Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry

The over-expression of aminopeptidase N on diverse malignant cells is associated with the tumor angiogenesis and metastasis. In this report, one new series of leucine ureido derivatives containing the triazole moiety was designed, synthesized and evaluated as APN inhibitors. Among them, compound 13v showed the best APN inhibition with an IC50 value of 0.089 ± 0.007 μM, which was two orders of magnitude lower than that of bestatin (IC50 = 9.4 ± 0.5 μM). Compound 13v also showed dose-dependent anti-angiogenesis activities. Even at the lower concentration (10 μM), compound 13v presented similar anti-angiogenesis activity compared with bestatin at 100 μM in both the human umbilical vein endothelial cells (HUVECs) capillary tube formation assay and the rat thoracic aorta rings test. Moreover, compared with bestatin, 13v exhibited comparable, if not better in vivo anti-metastasis activity in a mouse H22 pulmonary metastasis model.

Synthesis and leishmanicidal activity of eugenol derivatives bearing 1,2,3-triazole functionalities

In this paper, it is described the synthesis and the evaluation of the leishmanicidal activity of twenty-six eugenol derivatives bearing 1,2,3-triazole functionalities. The evaluation of the compounds on promastigotes of Leishmania amazonensis (WHOM/BR/75/Josefa) showed that eugenol derivatives present leishmanicidal activities with varying degrees of effectiveness. The most active compound, namely 4-(3-(4-allyl-2-methoxyphenoxy)propyl)-1-(4-methylbenzyl)-1H-1,2,3-triazole (7k) (IC50 = 7.4 ± 0.8 μmol L?1), also targeted Leishmania parasites inside peritoneal macrophages (IC50 = 1.6 μmol L?1) without interfering with cell viability. The cytotoxicity of 7k against macrophage cells presented IC50 of 211.9 μmol L?1 and the selective index was equal to 132.5. Under similar conditions, compound 7k was more effective than glucantime and pentamidine, two drugs currently in the clinic. In addition, theoretical calculations showed that this compound also presents most physicochemical and pharmacokinetic properties within the ranges expected for orally available drugs. It is believed that eugenol bearing 1,2,3-triazole functionalities may represent a scaffold to be explored toward the development of new agents to treat leishmaniasis.

NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis,